Phreesia, Inc.
PHR Healthcare Health Information Services
Phreesia, Inc.’s revenue for fiscal 2026 (year ended January 2026) was $480.6 million, up 14.5% from fiscal 2025. In the quarter to July 2026, revenue grew 10.4%, EPS grew 200.0%, free cash flow grew 43.5% and total debt rose 3,191.9%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
Follow PHR
Phreesia, Inc. (PHR) EV/Sales
As of 16 October 2026, Phreesia, Inc. (PHR) trades at a EV/Sales of 1.5×. Over the past ten years it has ranged from 0.0× (July 2019) to 20.0× (February 2021); the current reading is higher than 9% of that period. That is below the Health Information Services industry median of 2.6× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2026 | 1.9× | (50.44%) |
| FY2025 | 3.7× | 1.31% |
| FY2024 | 3.7× | (42.32%) |
| FY2023 | 6.4× | 8.61% |
| FY2022 | 5.9× | (63.96%) |
| FY2021 | 16.4× | 262.51% |
| FY2020 | 4.5× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jul 2026 | 1.5× | 9.16% |
| Apr 2026 | 1.3× | (27.82%) |
| Jan 2026 | 1.9× | (32.02%) |
| Oct 2025 | 2.7× | (19.35%) |
| 28 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| MDRX Veradigm Inc. compare | 0.6× |
| EVH Evolent Health, Inc compare | 0.6× |
| TDOC Teladoc Health, Inc. compare | 0.9× |
| PHR Phreesia, Inc. | 1.5× |
| WEAV Weave Communications, Inc. compare | 2.0× |
| OMDA Omada Health, Inc. compare | 2.8× |
| HSTM HealthStream, Inc. compare | 2.9× |
| NRC National Research Corporation compare | 3.8× |
| SOPH SOPHiA GENETICS SA compare | 5.1× |
| Health Information Services industry median | 2.6× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)